Immunome Inc. financial data

Symbol
IMNM on Nasdaq
Industry
Pharmaceutical Preparations
Location
18702 N. Creek Parkway, Suite 100, Bothell, Washington
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 577 % +104%
Debt-to-equity 43.3 % -37.3%
Return On Equity -221 % -56.7%
Return On Assets -154 % -84.8%
Operating Margin -1.87K %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 59.7M shares +389%
Common Stock, Shares, Outstanding 59.7M shares +390%
Entity Public Float 75.5M USD +121%
Common Stock, Value, Issued 6K USD +500%
Weighted Average Number of Shares Outstanding, Basic 51.5M shares +323%
Weighted Average Number of Shares Outstanding, Diluted 51.5M shares +323%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 12.7M USD -56.5%
Research and Development Expense 34.5M USD +80.8%
General and Administrative Expense 22.7M USD +75.3%
Operating Income (Loss) -237M USD -699%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -232M USD -686%
Earnings Per Share, Basic -7.54 USD/shares -204%
Earnings Per Share, Diluted -7.54 USD/shares -204%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 270M USD +507%
Assets, Current 313M USD +573%
Property, Plant and Equipment, Net 4.3M USD +370%
Operating Lease, Right-of-Use Asset 1.46M USD +534%
Other Assets, Noncurrent 568K USD
Assets 320M USD +565%
Accounts Payable, Current 7.18M USD +117%
Employee-related Liabilities, Current 1.03M USD +24.8%
Contract with Customer, Liability, Current 12.7M USD -30%
Liabilities, Current 30.8M USD +23.9%
Contract with Customer, Liability, Noncurrent 2.21M USD -76.6%
Deferred Income Tax Liabilities, Net 378K USD +1119%
Operating Lease, Liability, Noncurrent 1.21M USD
Other Liabilities, Noncurrent 1.34M USD +2061%
Liabilities 34.2M USD -0.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax 4K USD
Retained Earnings (Accumulated Deficit) -352M USD -193%
Stockholders' Equity Attributable to Parent 286M USD +1960%
Liabilities and Equity 320M USD +565%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -11.2M USD -146%
Net Cash Provided by (Used in) Financing Activities 219M USD +645326%
Net Cash Provided by (Used in) Investing Activities -37.2M USD -35024%
Common Stock, Shares Authorized 300M shares +50%
Common Stock, Shares, Issued 59.7M shares +390%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 171M USD +610%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 270M USD +506%
Deferred Tax Assets, Valuation Allowance 39.8M USD +30.1%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 40.2M USD +31.2%
Payments to Acquire Property, Plant, and Equipment 2.16M USD +1942%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -130M USD -2933%
Deferred Tax Assets, Operating Loss Carryforwards 22.8M USD +11%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 37K USD 0%
Additional Paid in Capital 638M USD +376%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 157K USD +67%
Deferred Tax Assets, Net of Valuation Allowance 378K USD +1119%
Share-based Payment Arrangement, Expense 7.16M USD +36.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%